ETFs Protagonist Therapeutics, Inc.

PTGX

US74366E1029

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2026-07-14 EDT			5-day change	1st Jan Change
131.27 ^USD	+1.06%		-6.80%	+50.30%

07-07	Truist Raises Price Target on Protagonist Therapeutics to $145 From $121, Keeps Buy Rating	MT
06-25	Protagonist Therapeutics Insider Sold Shares Worth $1,061,460, According to a Recent SEC Filing	MT

Protagonist Therapeutics, Inc. is a biopharmaceutical company with a technology platform that enables de novo discovery of peptide therapeutics. The Company's programs fall into three therapeutic areas: inflammation and immunology (I&I), hematology, and metabolic diseases. Its clinical and pre-clinical programs address biologically and commercially validated targets, including IL-17 oral peptide antagonist PN-881, obesity triple agonist peptide PN-477, obesity dual agonist peptide PN-458, oral small molecule hepcidin functional mimetic PN-8047, and IL-4 and amylin programs. The ICOTYDE (icotrokinra) is used for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age or older who weigh at least 40 kg and are candidates for systemic therapy or phototherapy. Rusfertide is an investigational injectable mimetic of the natural hormone hepcidin in development for the treatment of the rare blood disorder polycythemia vera (PV).

Employees

131

Sector

Biotechnology & Medical Research

More about the company